BlossomHill Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BlossomHill Therapeutics, Inc. - overview
Established
2020
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Founded in 2020 and based in California, US, BlossomHill Therapeutics, Inc. operates as a molecule drug discovery and development company. The company was co-founded by President and CEO Dr. J.
Jean Cui and Dr. Y. Peter Li. In December 2025, BlossomHill Therapeutics, Inc.
raised USD 84 million in series B funding co-led by Janus Henderson Investors, BioTrack Capital and Brahma Capital, with participation from Cormorant Asset Management, OrbiMed Advisors, Vivo Capital, and Plaisance Capital Management LLC. BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology, identifying key clinical needs, and discovering autoimmune disorders. The company plans to use the December 2025 funding to continue clinical testing of its main cancer drug candidates and to support development of its other oncology programs.
Current Investors
OrbiMed Advisors, Vivo Capital, Cormorant Asset Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.bhtherapeutics.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.